See the Full Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Social Media
Elon Musk
Artificial Intelligence
Natural Disasters
Donald Trump
Republican Party
Soccer
Security
US Politics
Immigration
Democratic Party
Education
Published • loading... • Updated

ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

Summary by The Daily News
WHIPPANY, N.J.--(BUSINESS WIRE)--May 28, 2025-

3 Articles

All
Left
Center
2
Right
The Daily NewsThe Daily News
Reposted by
Post RegisterPost Register
Center

ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

WHIPPANY, N.J.--(BUSINESS WIRE)--May 28, 2025-

Read Full Article
Baylor College of MedicineBaylor College of Medicine

S2312: Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer

S2312: Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer Andrew Phifer Wed, 05/28/2025

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Daily News broke the news in on Wednesday, May 28, 2025.
Sources are mostly out of (0)

Similar News Topics

New Jersey

New Jersey

News
For You
SearchBlindspotLocal